This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Dr Radich is a ...
Patients who achieved a major molecular response (MMR; BCR-ABL1 ≤0.1%) within 3 months had a 4-year progression-free survival (PFS) rate of about 80%, whereas those who did not meet that landmark ...
Patients and Methods: We examined the methylation status of the CDH13 promoter in 179 chronic phase (CP)-CML patients and in 52 advanced-phase samples and correlated it with mRNA expression using ...
76.7% complete cytogenetic response rate achieved in patients who failed second-generation TKI first-line therapy Molecular responses continue to deepen with extended treatment duration, reaching 60% ...
Please provide your email address to receive an email when new articles are posted on . The indication applies to use of the agent by pediatric patients aged 1 year or older with chronic phase ...
Early response to ponatinib appeared predictive of survival among certain patients with chronic myeloid leukemia, according to findings presented at Society of Hematologic Oncology Annual Meeting. The ...
A very unusual case of 2 chronic leukemias, chronic lymphocytic leukemia (CLL) and secondary chronic myeloid leukemia (CML) existing simultaneously in an older patient was treated with a pair of ...
Chronic myeloid leukemia (CML) is a type of blood cancer. CML is Philadelphia chromosome-positive (Ph+) when pieces of chromosomes 9 and 22 break off and swap places. This creates a new abnormal ...
The FDA approved Bosulif for children aged 1 and older with newly diagnosed or resistant/intolerant chronic myelogenous leukemia. The Food and Drug Administration ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback